Log-in / Create Account  
 
DIA 2013 49th Annual Meeting
Click here to go to the previous page
Bayesian Methods in Medical Product Development and Comparative Effectiveness
Track : Track 15: Statistical Science and Quantitative Thinking
Program Code: 429
Date: Thursday, June 27, 2013
Time: 10:45 AM to 12:15 PM  EST
Location: 157AB
CHAIR :
 David Ohlssen, PhD (SCHNON), Senior Expert Methodologist, Novartis Pharmaceuticals Corporation, United States
SPEAKER (S):
 Karen Price, (SPKNON), Research Advisor, Eli Lilly and Company, United States
 Bradley P. Carlin, PhD,MS (SPKSUP), Professor and Head of Biostatistics, University of Minnesota, United States
Lisa M. LaVange, PhD (SPKAGY), Director, Office of Biostatistics, Office of Translational Science, CDER, FDA, United States
Description
This session will discuss the importance of Bayesian methods in medical product development. We will also highlight the recent efforts of the Bayesian DIA working group.

Session Recording
(Code: 429)
DIA 2013 Attendee:
Attendees Login
  
This session is a part of:
DIA 2013 Live Learning Center
CON5 Comp Access: Thursday Online Access Package - June 27, 2013
Handout Online
(Code: 429)
DIA 2013 Attendee:
Attendees Login
  
This session is a part of:
DIA 2013 Live Learning Center
CON5 Comp Access: Thursday Online Access Package - June 27, 2013
Bayesian Methods in Medical Product Development and Comparative Effectiveness